Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome

Next Previous
Trial Profile

A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plozasiran (Primary)
  • Indications Hyperlipoproteinaemia type I; Hypertriglyceridaemia
  • Focus Adverse reactions; First in man
  • Sponsors Arrowhead Pharmaceuticals

Most Recent Events

  • 15 Nov 2021 According to an Arrowhead Pharmaceuticals media release, results from this trial were presented at the American Heart Association (AHA) Scientific Sessions 2021.
  • 15 Nov 2021 Results published in an Arrowhead Pharmaceuticals Media Release.
  • 01 Nov 2021 According to an Arrowhead Pharmaceuticals media release, results from this trial will be presented at the American Heart Association (AHA) Scientific Sessions 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top